Centrexion Therapeutics acquired three pain compounds from Boehringer Ingelheim GmbH for undisclosed financial terms, adding to its pipeline of non-opioid, non-surgical pain programs.

Centrexion was founded in November 2013 and is led by former Celgene Chairman and CEO, Sol Barer, Ph.D., who chairs the company’s Board of Directors, and Jeffrey Kindler, former Chairman and CEO of Pfizer, who serves as the company’s CEO. The company is well financed having raised $58 million to-date.